262 related articles for article (PubMed ID: 25527566)
1. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
[No Abstract] [Full Text] [Related]
2. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S; Haferlach T; Grossmann V; Alpermann T; Kowarsch A; Haferlach C; Kern W; Schnittger S
Haematologica; 2013 Feb; 98(2):e15-7. PubMed ID: 22929973
[No Abstract] [Full Text] [Related]
3. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
4. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
[TBL] [Abstract][Full Text] [Related]
5. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
6. Refractory anemia with ring sideroblasts.
Malcovati L; Cazzola M
Best Pract Res Clin Haematol; 2013 Dec; 26(4):377-85. PubMed ID: 24507814
[TBL] [Abstract][Full Text] [Related]
7. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
[No Abstract] [Full Text] [Related]
8. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
9. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.
Conte S; Katayama S; Vesterlund L; Karimi M; Dimitriou M; Jansson M; Mortera-Blanco T; Unneberg P; Papaemmanuil E; Sander B; Skoog T; Campbell P; Walfridsson J; Kere J; Hellström-Lindberg E
Br J Haematol; 2015 Nov; 171(4):478-90. PubMed ID: 26255870
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
11. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
Yoshimi A; Abdel-Wahab O
Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
[TBL] [Abstract][Full Text] [Related]
12. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
13. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
14. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
15. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
16. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
[TBL] [Abstract][Full Text] [Related]
17. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
[No Abstract] [Full Text] [Related]
18. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H; Jankowska AM; Makishima H; Bodo J; Bejanyan N; Hsi ED; Sekeres MA; Maciejewski JP
Leuk Res; 2010 Aug; 34(8):969-73. PubMed ID: 20334914
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
